|
Jun 30
|
Regeneron Pharmaceuticals (NasdaqGS:REGN) Exits Multiple Russell Growth Indices
|
|
Jun 30
|
Former 23andMe CEO regains company control as $305m sale to nonprofit approved
|
|
Jun 30
|
Circle initiated, Disney upgraded: Wall Street's top analyst calls
|
|
Jun 26
|
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
|
|
Jun 25
|
Regeneron Launches $200 Million Donation Matching Program to Support Vision Care
|
|
Jun 25
|
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
|
|
Jun 24
|
Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?
|
|
Jun 24
|
Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization
|
|
Jun 23
|
UBS Lowers Price Target On Regeneron Pharmaceuticals, Inc. (REGN).
|
|
Jun 23
|
The Top 5 Analyst Questions From Regeneron’s Q1 Earnings Call
|
|
Jun 23
|
Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks
|
|
Jun 20
|
The Score: 23andMe, U.S. Steel, Accenture and More Stocks That Defined the Week
|
|
Jun 20
|
Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says
|
|
Jun 20
|
From $6B Valuation to Bankruptcy to Rescue: Wojcicki Reclaims 23andMe for $305M
|
|
Jun 20
|
Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
|
|
Jun 20
|
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
|
|
Jun 19
|
Shareholders Approve Bylaw Amendments at Regeneron Pharmaceuticals (NasdaqGS:REGN) Annual Meeting
|
|
Jun 19
|
Regeneron Pharmaceuticals, Inc. (REGN) Growth Story Shifts as Wells Fargo Maintains Hold
|
|
Jun 19
|
Celltrion opens new UK headquarters in Uxbridge, UK
|
|
Jun 17
|
Sector Update: Health Care Stocks Retreat Late Afternoon
|